The nature of 3, 4-methylenedioxymethamphetamine (MDMA)-induced serotonergic dysfunction: Evidence for and against the neurodegeneration hypothesis

Current Neuropharmacology

Volumn 9, Issue 1, 2011, Pages 84-90

  Biezonski, Dominik K ^a,b   Meyer, Jerrold S ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Biochemical downregulation; Gene expression; MDMA; Neurodegeneration; Neurotoxicity; Serotonin; Serotonin transporter; Vesicular monoamine transporter 2

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; SEROTONIN; SEROTONIN RECEPTOR; VESICULAR MONOAMINE TRANSPORTER 2;

ARTICLE; AUTONOMIC NEUROPATHY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; ENVIRONMENTAL TEMPERATURE; EVIDENCE BASED MEDICINE; HIPPOCAMPAL CA3 REGION; HYPOTHESIS; IMMUNOREACTIVITY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARIETAL CORTEX; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE;

EID: 79953033163     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015911795017146     Document Type: Article

References (59)

1. Lyles, J.; Cadet, J.L. Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms. Brain Res. Rev., 2003, 42, 155-168.
2. Nichols, D.E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J. Psychoactive Drugs, 1986, 18, 305-313.
3. Ricaurte, G.A.; Bryan, G.; Strauss, L.; Seiden, L.; Schuster, C. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science, 1985, 229, 986-988.
4. Green, A.R.; Mechan, O.A.; Elliott, J.M.; O'Shea, E.; Colado, M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Pharmacol. Rev., 2003, 55, 463-508.
5. Battaglia, G.; Yeh, S.Y.; O'Hearn, E.; Molliver, M.E.; Kuhar, M.J.; De Souza, E.B. 3,4-Methylenedioxymethamphetamine and 3,4- methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J. Pharmacol. Exp. Ther., 1987, 242, 911-916.
6. Commins, D.L.; Vosmer, G.; Virus, R.M.; Woolverton, W.L.; Schuster, C.R.; Seiden, L.S. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J. Pharmacol. Exp. Ther., 1987, 241, 338-345.
7. O'Hearn, E.; Battaglia, G.; De Souza, E.B.; Kuhar, M.J.; Molliver M.E. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J. Neurosci., 1988, 8, 2788-2803.
8. Schmidt, C.J. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther., 1987, 240, 1-7.
9. Schmidt, C.J.; Wu, L.; Lovenberg, W. Methylenedioxymethamphetamine: A potentially neurotoxic amphetamine analogue. Eur. J. Pharmacol., 1986, 124, 175-178.
10. Stone, D.M.; Johnson, M.; Hanson, G.R.; Gibb, J.W. A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. Eur. J. Pharmacol., 1987, 134, 245-248.
11. Ricaurte, G.A.; DeLanney, L.E.; Irwin, I.; Langston, J.W. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res., 1988, 446, 165-168.
12. Ricaurte, G.A.; Forno, L.S.; Wilson, M.A.; DeLanney, L.E.; Irwin, I.; Molliver, M.E.; Langston, J.W. (±)-3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA, 1988, 260, 51-55.
13. Green, A.R.; O'Shea, E.; Saadat, K.S.; Elliott, J.M.; Colado, M.I. Studies on the effect of MDMA ('ecstasy') on the body temperature of rats housed at different ambient room temperatures. Br. J. Pharmacol., 2005, 146, 306-312.
14. Piper, B.J.; Meyer, J.S. Increased responsiveness to MDMA in adult rats treated neonatally with MDMA. Neurotoxicol. Teratol., 2006, 28, 95-102.
15. Battaglia, G.; Sharkey, J.; Kuhar, M.J.; de Souza, E.B. Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): assessment using quantitative autoradiography. Synapse, 1991, 8, 249-260.
16. Adori, C.; Andó, R.D.; Kovács, G.G.; Bagdy, G. Damage to serotonergic axons and immunolocalization of Hsp27, Hsp72, and Hsp90 molecular chaperones after a single dose of MDMA administration in Dark Agouti rat: temporal, spatial, and cellular patterns. J. Comp. Neurol., 2006, 497, 251-269.
17. Kovács, G.G.; Andó, R.D.; Adori, C.; Kirilly, E.; Benedek, A.; Palkovits, M.; Bagdy, G. Single dose of MDMA causes extensive decrement of serotoninergic fibre density without blockage of the fast axonal transport in Dark Agouti rat brain and spinal cord. Neuropathol. Appl. Neurobiol., 2007, 33, 193-203.
18. Meyer, J.S.; Grande, M.; Johnson, K.; Ali, F.S. Neurotoxic effects of MDMA (ecstasy) administration to neonatal rats. Int. J. Dev. Neurosci., 2004, 22, 261-271.
19. Meyer, J.S.; Piper, B.J.; Vancollie, V.E. Development and characterization of a novel animal model of intermittent MDMA ("Ecstasy") exposure during adolescence. Ann. N. Y. Acad. Sci., 2008, 1139, 151-163.
20. Xie, T.; Tong, L.; McLane, M.W.; Hatzidimitriou, G.; Yuan, J.; McCann, U.; Ricaurte, G. Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsycho pharmacology, 2006, 31, 2639-2651.
21. Molliver, M.E.; Berger, U.V.; Mamounas, L.A.; Molliver, D.C.; O'Hearn, E.; Wilson, M.A. Neurotoxicity of MDMA and related compounds: anatomic studies. Ann. N.Y. Acad. Sci., 1990, 600, 649-661.
22. Battaglia, G.; Yeh, S.Y.; De Souza, E.B. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem. Behav., 1988, 29, 269-274.
23. Fischer, C.; Hatzidimitriou, G.; Wlos, J.; Katz, J.; Ricaurte, G. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, ecstasy). J. Neurosci., 1995, 15, 5476-5485.
24. Scanzello, C.R.; Hatzidimitriou, G.; Martello, A.L.; Katz, J.L.; Ricaurte, G.A. Serotonergic recovery after (+/-)3,4-(methylenedioxy) methamphetamine injury: observations in rats. J. Pharmacol. Exp. Ther., 1993, 264, 1484-1491.
25. Ricaurte, G.A.; Martello, A.L.; Katz, J.L.; Martello, M.B. Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J. Pharmacol. Exp. Ther., 1992, 261, 616-622.
26. Jensen, K.F.; Olin, J.; Haykal-Coates, N.; O'Callaghan, J.; Miller, D.B.; de Olmos, J.S. Mapping toxicant-induced nervous system damage with a cupric silver stain: a quantitative analysis of neural degeneration induced by 3,4-methylenedioxymethamphetamine. NIDA Res. Monogr., 1993, 136, 133-149.
27. Scallet, A.C.; Lipe, G.W.; Ali, S.F.; Holson, R.R.; Frith, C.H.; Slikker, W. Jr. Neuropathological evaluation by combined immunohistochemistry and degeneration-specific methods: application to methylenedioxymethamphetamine. Neurotoxicology, 1988, 9, 529-537.
28. Schmued, L.C. Demonstration and localization of neuronal degeneration in the rat forebrain following a single exposure to MDMA. Brain Res., 2003, 974, 127-133.
29. Callahan, B.T.; Cord, B.J.; Ricaurte, G.A. Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine. Synapse, 2001, 40, 113-121.
30. Cadet, J.L.; Krasnova, I.N.; Jayanthi, S.; Lyles, J. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox. Res., 2007, 11, 183-202.
31. Yamamoto, B.K.; Raudensky, J. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J. Neuroimmune Pharmacol., 2008, 3, 203-217.
32. Piñeyro, G.; Blier, P. Auto regulation of serotonin neurons: role in antidepressant drug action. Pharmacol. Rev., 1999, 51, 533-591.
33. O'Callaghan, J.P.; Miller, D.B. Quantification of reactive gliosis as an approach to neurotoxicity assessment. NIDA Res. Monogr., 1993, 136, 188-212.
34. Pubill, D.; Canudas, A.M.; Pallas, M.; Camins, A.; Camarasa, J.; Escubedo E. Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn Schmiedebergs Arch. Pharmacol., 2003, 367, 490-499.
35. Straiko, M.M.; Coolen, L.M.; Zemlan, F.P.; Gudelsky G.A. The effect of amphetamine analogs on cleaved microtubule-associated protein-tau formation in the rat brain. Neuroscience, 2007, 144, 223-231.
36. Wang, X.; Baumann, M.H.; Xu, H.; Rothman, R.B. 3,4- methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glialfibrillary acidic protein. Synapse, 2004, 53, 240-248.
37. Wang, X.; Baumann, M.H.; Xu, H.; Morales, M.; Rothman, R.B. (+/-)-3,4 Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane. J. Pharmacol. Exp. Ther., 2005, 314, 1002-1012.
38. Aguirre, N.; Barrionuevo, M.; Ramirez, M.J.; Del Río, J.; Lasheras, B. α-Lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity. Neuro Report, 1999, 10, 3675-3680.
39. Monks, T.J.; Jones, D.C.; Bai, F.; Lau, S.S. The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)methylenedioxymethamphetamine (ecstasy) toxicity. Ther. Drug Monit., 2004, 26, 132-136.
40. Wang, X.; Baumann, M.H.; Dersch, C.M.; Rothman, R.B. Restoration of 3,4-methylenedioxymethamphetamine-induced 5-HT depletion by the administration of L-5-hydroxytryptophan. Neuroscience, 2007, 148, 212-220.
41. Callaghan, P.D.; Owens, W.A.; Javors, M.A.; Sanchez, T.A.; Jones, D.J.; Irvine, R.J.; Daws, L.C. In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA), but not 3,4-methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in serotonin transporter function. J. Neurochem., 2007, 100, 617-627.
42. Kirilly, E.; Molnar, E.; Balogh, B.; Kantor, S.; Hansson, S.R.; Palkovits, M.; Bagdy, G. Decrease in REM latency and changes in sleep quality parallel serotonergic damage and recovery after MDMA: a longitudinal study over 180 days. Int. J. Neuropsychopharmacol., 2008, 11, 795-809.
43. Carneiro, A.M.D.; Blakely, R.D. Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter. J. Biol. Chem., 2006, 281, 24769-24780.
44. Biezonsk, D.K.; Meyer, J.S. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity. J. Neurochem., 2010, 112, 951-962.
45. Qian, Y.; Melikian, H.E.; Rye, D.B.; Levey, A.I.; Blakely, R.D. Identification and characterization of antidepressant-sensitive serotonin transporter proteins using site-specific antibodies. J. Neurosci., 1995, 15, 1261-1274.
46. Frey, K.; Kilbourn, M.; Robinson, T. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorallysensitizing doses of methamphetamine. Eur. J. Pharmacol., 1997, 334, 273-279.
47. Miller, G.W.; Erickson, J.D.; Perez, J.T.; Penland, S.N.; Mash, D.C.; Rye, D.B.; Levey, A.I. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp. Neurol., 1999, 156, 138-148.
48. Van der Borght. T.M.; Sima, A.A.F.; Kilbourn, M.R.; Desmond, T.J.; Kuhl, D.E.; Frey, K.A. [3H]Methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience, 1995, 68, 955-962.
49. Guilarte, T.R.; Nihei, M.K.; McGlothan, J.L.; Howard, A.S. Methamphetamine- induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity. Neuroscience, 2003, 122, 499-513.
50. Verney, C.; Baulac, M.; Berger, B.; Alvarez, C.; Vigny, A.; Helle, K.B. Morphological evidence for a dopaminergic terminal field in the hippocampal formation of young and adult rat. Neuroscience, 1985, 14, 1039-1052.
51. Fritschy, J.M.; Geffard, M.; Grzanna, R. The response of noradrenergic axons to systemically administered DSP-4 in the rat: an immunohistochemical study using antibodies to noradrenaline and dopamine-beta-hydroxylase. J. Chem. Neuroanat., 1990, 3, 309-321.
52. Vertes, R.P.; Linley, S.B. Comparison of projections of the dorsal and median raphe nuclei, with some functional considerations. Int. Congr. Ser., 2007, 1304, 98-120.
53. Gylys, K.H.; Fein, J.A.; Cole, G.M. Quantitative characterization of crude synaptosomal fraction (P-2) components by flow cytometry. J. Neurosci. Res., 2000, 61, 186-192.
54. Gylys, K.H.; Fein, J.A.; Yang, F.; Cole, G.M. Enrichment of presynaptic and postsynaptic markers by size-based gating analysis of synaptosome preparations from rat and human cortex. Cytometry, 2004, 60, 90-96.
55. Pubill, D.; Chipana, C.; Camins, A.; Pallàs, M.; Camarasa, J.; Escubedo, E. Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicol. Appl. Pharmacol., 2005, 204, 57-68.
56. Wolf, M.E.; Kapatos, G. Flow cytometric analysis of rat striatal nerve terminals. J. Neurosci., 1989, 9, 94-105.
57. Ujike, H.; Takaki, M.; Kodama, M.; Kuroda, S. Gene expression related to synaptogenesis, neuritogenesis, and MAP kinase in behavioral sensitization to psychostimulants. Ann. N. Y. Acad. Sci., 2002, 965, 55-67.
58. Stroemer, R.P.; Kent, T.A.; Hulsebosch, C.E. Enhanced neocortical neural sprouting, synaptogenesis, and behavioral recovery with Damphetamine therapy after neocortical infarction in rats. Stroke, 1998, 29, 2381-2395.
59. Piper, B.J.; Farelli, J.D.; Meyer, J.S. Dissociation between serotonin neurotoxicity and brain-derived neurotrophic factor induction following neonatal MDMA exposure in rats. Dev. Neurosci., 2009, 31, 90-94.